class action lawsuit semaglutide Lawsuits claiming Ozempic, other GLP-1s led to blindness become second mass litigation over the drugs Ozempic Lawsuit for Blindness, Stomach

Periodontal treatment decreases levels of antibodies to Porphyromonas gingivalis and citrulline in patients with rheumatoid arthritis and periodontitis

If maximum average weight loss is your priority and you tolerate dual-agonists well, Tirzepatide may offer a stronger effect for some patients

Michaud, Lausanne (Mdecine de ladolescence)

According to US obesity treatment guidelines, clinicians should consider whether to continue therapy if a patient has not lost at least 5% of baseline weight after approximately 3 months on the maintenance dose

ELISA kits provide a cost-effective and high-throughput alternative, though potential antibody cross-reactivity requires careful validation

WHO tarafndan yaymlanan bu rehber, obezitenin kresel bir halk sal sorunu olduuna dikkat ekerken, farmakolojik tedavilerin herkes iin uygun zmler olarak sunulmamas gerektiini vurguluyor